Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM355 in Refractory Systemic Lupus Erythematosus
NCT07104344Active, not recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of CM355 in systemic lupus erythematosus (SLE), sponsored by The Second Xiangya Hospital. Primary endpoint: Adverse Events at 1 year. Started Sep 2025; status: active, not recruiting.
02
Drugs
CM355
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07104344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104344.